{"id":34707,"date":"2017-05-24T21:35:11","date_gmt":"2017-05-24T20:35:11","guid":{"rendered":"https:\/\/bioengineer.org\/utas-abexxa-biologics-named-one-of-40-best-university-startups-2017-by-ncet2\/"},"modified":"2017-05-24T21:35:11","modified_gmt":"2017-05-24T20:35:11","slug":"utas-abexxa-biologics-named-one-of-40-best-university-startups-2017-by-ncet2","status":"publish","type":"post","link":"https:\/\/bioengineer.org\/utas-abexxa-biologics-named-one-of-40-best-university-startups-2017-by-ncet2\/","title":{"rendered":"UTA&#8217;s AbeXXa Biologics named one of 40\u00a0Best University Startups 2017\u00a0by NCET2"},"content":{"rendered":"<p>(University of Texas at Arlington) AbeXXa Biologics, a faculty startup at The University of Texas at Arlington, was named one of the 40 &#039;Best University Startups 2017&#039; by the National Council of Entrepreneurial Tech Transfer. AbeXXa is identifying a new series of biomarkers or targets for cancer from the many thousands of proteins found within a tumor cell, a new field of research that could potentially result in immunotherapies that prove effective for a broad range of patients.<\/p>\n<p>############<\/p>\n<p \/><!--more--><\/p>\n<p><b>Story Source:  <\/b><a href=\"\/\/scienmag.com\">Materials<\/a>  provided by <strong><span style=\"color: #ff0000\">Scienmag<\/span><\/strong><\/p>\n<p \/>\n","protected":false},"excerpt":{"rendered":"<p>(University of Texas at Arlington) AbeXXa Biologics, a faculty startup at The University of Texas at Arlington, was named one of the 40 &#039;Best University Startups 2017&#039; by the National Counci..<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_review":[],"enable_review":"","type":"","name":"","summary":"","brand":"","sku":"","good":[],"bad":[],"score_override":"","override_value":"","rating":[],"price":[],"jnews_override_counter":[],"footnotes":""},"categories":[185],"tags":[],"class_list":["post-34707","post","type-post","status-publish","format-standard","hentry","category-science-news"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts\/34707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/comments?post=34707"}],"version-history":[{"count":0,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts\/34707\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/media?parent=34707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/categories?post=34707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/tags?post=34707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}